Ginkgo Bioworks Holdings (DNA) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Ginkgo Bioworks Holdings $5.67, price $8.58, upside -33.9%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ginkgo Bioworks Holdings for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $5.36 – $596.80 · fair‑value band $4.23 – $8.46 · the $8.58 price screens above the $5.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Ginkgo Bioworks in your weekly email
Every Wednesday you see whether Ginkgo Bioworks is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Show more
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Stock analysis
Ginkgo Bioworks Holdings (DNA) currently trades at $8.58, while our model-based Fair Value estimate is $5.67, implying the stock looks roughly 51.3% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $4.23 (bear) to $8.46 (bull), the price of $8.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Ginkgo Bioworks Holdings reported revenue of $170M in FY2025 versus $314M in FY2021, a compound −14.2%/yr. Reported net income was −$313M in FY2025.
Key figures
Market cap $599M · P/S ratio 3.96 · EPS (TTM) $−5.38 · Net margin −201% · Return on equity −56.0% · Return on assets (EBIT) −59.2% · Operating margin −367% · Revenue (TTM) $151M.
What moves the price
The share trades about 47% below its 52-week high and 57% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −34%, DNA screens richer than that median.
Fair Value models
Bear $4.23Fair Value $5.67Bull $8.46
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−25.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−178.8% (2020) → −185.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Compare Ginkgo Bioworks Holdings with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−34% · Above median
Profitability
Return on assets−16% · Below median
Net margin (TTM)−184% · Bottom 25%
Growth and dividend
Revenue growth−49% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ginkgo Bioworks Holdings (DNA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $5.67 versus a price of $8.58, about −34% upside (overvalued).
What is the fair value of DNA?
Our model-based fair value for Ginkgo Bioworks Holdings is $5.67 (as of Sep 23, 2026), built from audited fundamentals. The current price: $8.58.
What is the quality score of DNA?
Ginkgo Bioworks Holdings has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ginkgo Bioworks Holdings (DNA)?
Our model-based price target is the fair value of $5.67 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $4.23, optimistic scenario $8.46. It is a calculation from audited fundamentals, not an analyst target.
What is the Ginkgo Bioworks Holdings stock forecast for 2026?
Our models put fair value at $5.67, about −34% upside versus a price of $8.58 (overvalued). Cautious scenario $4.23, optimistic scenario $8.46. The calculation is refreshed regularly with new filings.
What is the revenue of Ginkgo Bioworks Holdings (DNA)?
Ginkgo Bioworks Holdings reported trailing-twelve-month revenue of about $151M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Ginkgo Bioworks Holdings (DNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ginkgo Bioworks Holdings it is $5.67 per share (as of Sep 23, 2026), against a price of $8.58. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Ginkgo Bioworks Holdings stock overvalued or undervalued in 2026?
As of Sep 23, 2026, DNA trades above its calculated fair value: price $8.58, fair value $5.67, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DNA?
No. The price is what the market pays today ($8.58); the fair value is what the company's own numbers justify ($5.67). For Ginkgo Bioworks Holdings the two are $2.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ginkgo Bioworks Holdings worth?
The market values Ginkgo Bioworks Holdings at about $599M (market capitalisation, as of Sep 23, 2026). Per share that is $8.58; our models calculate a fair value of $5.67 per share.
What do the bullish and bearish scenarios say about DNA?
Our models span a range for Ginkgo Bioworks Holdings: cautious scenario $4.23, base $5.67, optimistic $8.46 per share (as of Sep 23, 2026, price $8.58). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ginkgo Bioworks Holdings (DNA)?
Balance-sheet figures for Ginkgo Bioworks Holdings (as of Sep 23, 2026): return on equity −56.0%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is DNA from its 52-week high?
Ginkgo Bioworks Holdings trades at $8.58, about 47% below its 52-week high of $16.14 and 57% above the low of $5.48 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.67 is for.
Which stocks are comparable to Ginkgo Bioworks Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ginkgo Bioworks Holdings stock attractive at the current price?
The data as of Sep 23, 2026: price $8.58, calculated fair value $5.67 (−34%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DNA calculated?
We run Ginkgo Bioworks Holdings through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Ginkgo Bioworks Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ginkgo Bioworks Holdings (DNA)?
The closing price on Sep 23, 2026 was $8.58. Our model-based fair value is $5.67, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ginkgo Bioworks Holdings right now?
Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($4.23 to $8.46) leaves room in how you read the outcome.
Key figures of Ginkgo Bioworks Holdings
How large is the market capitalisation of Ginkgo Bioworks Holdings (DNA)?
The market capitalisation of Ginkgo Bioworks Holdings is $599M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ginkgo Bioworks Holdings (DNA)?
The price-to-sales ratio of Ginkgo Bioworks Holdings is 3.96 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ginkgo Bioworks Holdings (DNA)?
Earnings per share at Ginkgo Bioworks Holdings are $−5.38. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ginkgo Bioworks Holdings (DNA)?
The net margin of Ginkgo Bioworks Holdings is −201% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ginkgo Bioworks Holdings (DNA)?
The return on equity (ROE) of Ginkgo Bioworks Holdings is −56.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ginkgo Bioworks Holdings (DNA)?
On an EBIT basis the return on assets of Ginkgo Bioworks Holdings is −59.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ginkgo Bioworks Holdings (DNA)?
The operating margin of Ginkgo Bioworks Holdings is −367% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ginkgo Bioworks Holdings (DNA)?
Revenue at Ginkgo Bioworks Holdings is growing −49.1% versus a year earlier (3y avg −29.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ginkgo Bioworks Holdings (DNA) generate?
The free cash flow of Ginkgo Bioworks Holdings is −$179M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ginkgo Bioworks Holdings (DNA) carry?
The net debt of Ginkgo Bioworks Holdings is $273M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ginkgo Bioworks Holdings in the live analysis
One click puts Ginkgo Bioworks Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026